Respiratory Syncytial Virus: Current Progress in Vaccine Development

Viruses

Rajeev Rudraraju¹  Bart G. Jones¹  Robert Sealy¹  Sherri L. Surman¹ 

[1] Department of Infectious Diseases, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA; E-Mails:

关键词: respiratory syncytial virus;    candidate vaccines;    protective immunity;   

DOI  :  10.3390/v5020577

来源: mdpi

【 摘 要 】

Respiratory syncytial virus (RSV) is the etiological agent for a serious lower respiratory tract disease responsible for close to 200,000 annual deaths worldwide. The first infection is generally most severe, while re-infections usually associate with a milder disease. This observation and the finding that re-infection risks are inversely associated with neutralizing antibody titers suggest that immune responses generated toward a first RSV exposure can significantly reduce morbidity and mortality throughout life. For more than half a century, researchers have endeavored to design a vaccine for RSV that can mimic or improve upon natural protective immunity without adverse events. The virus is herein described together with the hurdles that must be overcome to develop a vaccine and some current vaccine development approaches.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.